Arcutis Biotherapeutics Inc(ARQT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 152.97 | EPS (ttm) | 0.21 | Insider Own | 12.88% | Shs Outstand | 125.6M | Perf Week | -3.47% |
| Market Cap | 3.98B | Forward P/E | 24.14 | EPS next Y | 173.44% | Insider Trans | -0.77% | Shs Float | 109.5M | Perf Month | 15.92% |
| Enterprise Value | 3.86B | PEG | - | EPS next Q | 0.18 | Inst Own | 95.79% | Short Float | 18.71% | Perf Quarter | 13.71% |
| Income | 0.03B | P/S | 8.58 | EPS this Y | 469.23% | Inst Trans | 3.31% | Short Ratio | 8.37 | Perf Half Y | 36.02% |
| Sales | 0.46B | P/B | 18.04 | EPS next 5Y | - | ROA | 6.78% | Short Interest | 20.49M | Perf YTD | 9.09% |
| Book/sh | 1.76 | P/C | 16.67 | EPS past 3/5Y | 71.8% 49.34% | ROE | 15.86% | 52W High | -4.86% ($33.30) | Perf Year | 61.3% |
| Cash/sh | 1.9 | P/FCF | 101.71 | Sales past 3/5Y | 367.27% - | ROIC | 8.7% | 52W Low | 64.19% ($19.30) | Perf 3Y | 1256.75% |
| Dividend Est. | - | EV/EBITDA | 103.69 | EPS Y/Y TTM | 129.74% | Gross Margin | 91.14% | Volatility(W/M) | 3.52% 5.01% | Perf 5Y | 50.07% |
| Dividend TTM | - | EV/Sales | 8.31 | Sales Y/Y TTM | 76.11% | Oper. Margin | 7.38% | ATR (14) | 1.42 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.67 | EPS Q/Q | 188.25% | Profit Margin | 6.15% | RSI (14) | 65.62 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.92 | Sales Q/Q | 59.33% | SMA20 | 12.88% ($28.07) | Beta | 1.69 | Target Price | $39.12 |
| Payout | - | Debt/Eq | 0.52 | Earnings | 2026/11/4 | SMA50 | 20.37% ($26.32) | Rel Volume | 0.91 | Prev Close | $31.81 |
| Employees | 354 | LT Debt/Eq | 0.49 | EPS/Sales Surpr. | 99.64% 9.26% | SMA200 | 25.88% ($25.17) | Avg Volume(3M) | 2.45M | Price | $31.68 |
| IPO | 2020/1/31 | Option/Short | Yes/Yes | Trades | 12156 | Volume | 2,224,166 | Change | -0.41% |
A U.S. biotech company that develops and commercializes treatments for skin diseases. It focuses on developing and commercializing therapies for skin conditions such as psoriasis and eczema, and is gaining attention as it advances the commercialization of new drugs and expands prescriptions. The company is a biotech firm specialized in treatments for skin diseases.
Over the past 1 year, on the higher side
5% below its 1-year high.
Traded about as much as usual. That is 91% of its average volume.
Next earnings report: November 4
7 days to go.
ARQT makes money exceptionally well
Of every $100 in sales, $7.38 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +469.2% this year.
Tap to view numbers
However, it looks expensive
Counting its debt, for $100 of yearly operating cash you would pay $10,369. Peers typically go for $4,457.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +50.1%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 95.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #61 of 594 in the industry
Based on market cap of $4B.
LEGN#58 Legend Biotech Corp ADR $4B PER - 
ABCL#59 AbCellera Biologics Inc $4B PER - 
RLAY#60 Relay Therapeutics Inc $4B PER - ARQT#61 Arcutis Biotherapeutics Inc $4B PER 153.0 
TNGX#62 Tango Therapeutics Inc $4B PER - 
FAQ
What kind of company is ARQT?
ARQT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ARQT?
The market cap of ARQT is approximately $4.0B, ranking 1,547 within its sector.
What is the P/E ratio of ARQT?
ARQT has a P/E ratio of approximately 153.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ARQT?
ARQT has recorded a 52-week high of $33.30 and a low of $19.30.
